Notably, a specific USP1 inhibitor, Pimozide, a US FDA-approved antipsychotic drug, exhibits potent anticancer effects in preclinical models of AML, T cell leukemia, and diffuse large B cell lymphoma, with minimal toxicity [76, 87, 88]. Here, USP1 is linked to T-cell leukemia.